<DOC>
	<DOCNO>NCT01318811</DOCNO>
	<brief_summary>Heparin commonly use anticoagulation extracorporeal circuit continuous renal replacement therapy ( CRRT ) optimal mode delivery yet validate . Our study compare dilute heparin standard concentration heparin . The investigator hypothesize heparin deliver dilute solution augment coat filter fiber anticoagulant , decrease clot event increase filter life . By improve delivery heparin filter circuit , clot event disrupt dialysis , less heparin would require extra-corporeal circuit thus less heparin would deliver back patient blood return machine . By expose patient less heparin hypothesize few bleeding event would occur , make dialysis treatment safer . If filter 's fiber remain patent filter functional long period time , CRRT would also effective .</brief_summary>
	<brief_title>A Comparison Dilute Versus Concentrated Heparin CRRT Anticoagulation</brief_title>
	<detailed_description>Our study compare two protocol use heparin anticoagulation extra-corporeal circuit CRRT . Study subject recruit patient start continuous venovenous hemodialysis ( CVVHD ) intensive care unit Vanderbilt University Medical Center ( VUMC ) . Once enrolled , patient pragmatic cluster-randomized ( month entry ) one two study arm . Arm A receive dilute heparin arm B receive standard concentrate heparin approach standard practice VUMC . Heparin deliver intravenous infusion proximal dialysis filter group . Replacement extra-corporeal circuit , include dialysis filter , perform several circumstance : stop CRRT subject transport ICU procedure study , machine malfunction , clot filter . All CRRT circuit filter , regardless patency , replace 72 hour per dialysis unit protocol . Only data first filter use CVVHD use study subject 's enrollment end replacement extracorporeal circuit filter . Study subject receive standard care duration study inpatient Nephrology team control aspects dialysis treatment . Changes heparin infusion rate make base heparin nomogram study apply either arm . A copy nomogram provide inpatient Nephrology team make adjustment heparin infusion require maintain blood anticoagulation level goal . The principle investigator ( PIs ) available time pager phone address question regard proper adjustment heparin infusion monitor heparin dose change ensure consistency implementation study protocol . The following summary two intervention ( arm ) : Treatment Algorithm Dilute heparin : Patients dilute heparin arm ( enrolled odd calendar month ) receive systemic loading dose heparin 15 unit per kilogram weight ( heparin dos round near 100 unit ) rapid ( &lt; 10 second ) intravenous bolus . The heparin concentration rapid intravenous load bolus 1000 unit per mL . Then maintenance rate heparin 7.5 U/Kg per hour start . Heparin deliver solution 2 units/mL infusion prepare 2,000 unit heparin 1,000 mL 0.9 % NaCl deliver intravenously proximal dialysis filter . Standard concentrate heparin : Patients concentrate heparin arm ( enrol even calendar month ) receive systemic loading dose heparin 15 unit per kilogram weight* rapid ( &lt; 10 second ) intravenous bolus . The heparin concentration rapid intravenous load bolus arm also 1000 unit per mL . Then maintenance rate heparin 7.5 U/Kg per hour start deliver via syringe Prismaflex® proximal dialysis filter . The concentration heparin use 1,000 unit heparin per mL 0.9 % NaCl . Dose monitor adjustment : aPTT test measure baseline regular interval thereafter . Adjustment heparin dose make use heparin nomogram ( see ) aPTT target level great 35 second less 50 second . aPTT level monitor every six hour routinely . If significant change make heparin infusion rate due prolong aPTT , aPTT check short interval three hour ensure aPTT persistently supratherapeutic level could increase risk bleed complication . Nomogram heparin infusion : aPTT ( second ) &lt; 35 , infusion ( continue ) , infusion rate change ( increase 10 % ) , repeat aPTT ( 6 hour ) ; aPTT ( second ) 35 50 , infusion ( continue ) , infusion rate change ( change ) , repeat aPTT ( 6 hour ) ; aPTT ( second ) 51 60 , infusion ( stop 1/2 hour ) , infusion rate change ( decrease 10 % ) , repeat aPTT ( 3 hour ) ; aPTT ( second ) 61 70 , infusion ( stop 1 hour ) , infusion rate change ( decrease 20 % ) , repeat aPTT ( 3 hour ) ; aPTT ( second ) 71 80 , infusion ( stop 1.5 hour ) , infusion rate change ( decrease 20 % ) , repeat aPTT ( 3 hour ) ; aPTT ( second ) &gt; 80 , infusion ( stop 2 hour ) , infusion rate change ( decrease 20 % ) , repeat aPTT ( 3 hour ) ; For purpose study , data collect first filter use CVVHD treatment . Following end study enrollment period patient continue CVVHD heparin infusion discretion treat physician . Heparin infusion continue adjust base heparin nomogram .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Acute Kidney Injury</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>Age great 18 year Renal failure , electrolyte disturbance , volume overload require continuous venovenous hemodialysis ( CVVHD ) determine Nephrology consult service Age le 18 year Active bleeding Coagulopathy define baseline INR &gt; 1.8 , aPTT &gt; 45 second , platelet count &lt; 50 thousand/μL Active administration systemic anticoagulation ( warfarin , therapeutic unfractionated heparin , therapeutic enoxaparin ) Contraindication heparin ( allergy , thrombocytopenia platelet count &lt; 50 , know suspect heparin induce thrombocytopenia [ HIT ] ) Contraindication systemic anticoagulation ( recent surgical invasive procedure , significant bleeding disorder , concern intracranial bleeding , contraindication determine treat physician ) Administration drotrecogin ( Xigris™ ) Anticipated surgical invasive procedure would necessitate withdrawal anticoagulation within 72 hour Expected termination continuous renal replacement therapy ( CRRT ) death &lt; 24 hour The need 500 cc hour IV fluid deliver proximal filter purpose perform continuous venovenous hemofiltration ( CVVH ) continuous venovenous hemodiafiltration ( CVVHDF )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Heparin</keyword>
	<keyword>CRRT</keyword>
	<keyword>Continuous renal replacement therapy</keyword>
	<keyword>CVVHD</keyword>
	<keyword>Anticoagulation</keyword>
</DOC>